You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

LAMIVUDINE AND ZIDOVUDINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lamivudine And Zidovudine patents expire, and what generic alternatives are available?

Lamivudine And Zidovudine is a drug marketed by Aurobindo Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Cipla, Epic Pharma Llc, Hetero Labs Ltd Iii, Hetero Labs Ltd V, Lupin Ltd, Macleods Pharms Ltd, Natco, Norvium Bioscience, Pharmacare, and Strides Pharma. and is included in thirteen NDAs.

The generic ingredient in LAMIVUDINE AND ZIDOVUDINE is lamivudine; zidovudine. There are twenty-nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the lamivudine; zidovudine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lamivudine And Zidovudine

A generic version of LAMIVUDINE AND ZIDOVUDINE was approved as lamivudine; zidovudine by LUPIN LTD on May 15th, 2012.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LAMIVUDINE AND ZIDOVUDINE?
  • What are the global sales for LAMIVUDINE AND ZIDOVUDINE?
  • What is Average Wholesale Price for LAMIVUDINE AND ZIDOVUDINE?
Summary for LAMIVUDINE AND ZIDOVUDINE
Drug patent expirations by year for LAMIVUDINE AND ZIDOVUDINE
Recent Clinical Trials for LAMIVUDINE AND ZIDOVUDINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Johns Hopkins UniversityPhase 1/Phase 2
The Aurum Institute NPCPhase 1/Phase 2
Médecins Sans Frontières, BelgiumPhase 2

See all LAMIVUDINE AND ZIDOVUDINE clinical trials

US Patents and Regulatory Information for LAMIVUDINE AND ZIDOVUDINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 077558-001 May 5, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hetero Labs Ltd V LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 203259-001 Feb 3, 2014 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cipla LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 077411-001 Sep 7, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pharmacare LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 022018-001 Mar 17, 2017 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lupin Ltd LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 090246-001 May 15, 2012 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma Ltd LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 202418-001 May 15, 2012 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for LAMIVUDINE AND ZIDOVUDINE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Teva Pharma B.V.  Lamivudine/Zidovudine Teva lamivudine, zidovudine EMEA/H/C/001236
Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.
Withdrawn yes no no 2011-02-28
ViiV Healthcare BV Combivir lamivudine, zidovudine EMEA/H/C/000190
Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.,
Authorised no no no 1998-03-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.